Lexicon Pharmaceuticals Inc. Company Profile
NASDAQ: LXRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Lexicon Pharmaceuticals at a glance
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in The Woodlands, TX. Lexicon Pharmaceuticals is led by Dr. Michael S. Exton Ph.D. and employs about 81 people. At a market capitalization of $681.2 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001062822, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Lexicon Pharmaceuticals do?
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Business description based on the company's public filings.
Company information
- Legal name
- Lexicon Pharmaceuticals Inc.
- Ticker
- NASDAQ: LXRX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Michael S. Exton Ph.D.
- Employees
- 81
- Headquarters
- 2445 Technology Forest Boulevard, The Woodlands, TX, United States
- Phone
- 281 863 3000
- Website
- lexpharma.com
- Market cap
- $681.21M
- SEC CIK
- 0001062822
- Latest annual report
- 10-K · Mar 5, 2026
Companies similar to Lexicon Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| APMDApnimed Inc. | 16.09 | -6.70% | $669.84M | vs LXRX |
| NVCTNuvectis Pharma Inc. | 19.39 | -2.27% | $666.80M | vs LXRX |
| SGMTSagimet Biosciences Inc. Series A | 9.08 | -5.61% | $648.02M | vs LXRX |
| KURAKura Oncology Inc. | 6.91 | -5.99% | $634.88M | vs LXRX |
| OBXObsidian Therapeutics Inc. | 12.00 | -1.23% | $741.29M | vs LXRX |
| JANXJanux Therapeutics Inc. | 10.08 | -2.04% | $616.73M | vs LXRX |
| ABUSArbutus Biopharma Corporation | 4.02 | -1.23% | $616.24M | vs LXRX |
| OLMAOlema Oncology Inc. | 7.02 | -1.82% | $615.00M | vs LXRX |